Literature DB >> 19584855

Will integrin inhibitors have proangiogenic effects in the clinic?

Michael Weller, David Reardon, Burt Nabors, Roger Stupp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19584855     DOI： 10.1038/nm0709-726

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  7 in total

1.  Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jeannette M Dowell; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; Melissa Wagner; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

2.  Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

Authors:  L Burt Nabors; Tom Mikkelsen; Steven S Rosenfeld; Fred Hochberg; Narasimha S Akella; Joy D Fisher; Gretchen A Cloud; Yu Zhang; Kathryn Carson; Sabine M Wittemer; A Dimitrios Colevas; Stuart A Grossman
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

3.  Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.

Authors:  David A Reardon; Karen L Fink; Tom Mikkelsen; Timothy F Cloughesy; Alison O'Neill; Scott Plotkin; Michael Glantz; Paula Ravin; Jeffrey J Raizer; Keith M Rich; David Schiff; William R Shapiro; Susan Burdette-Radoux; Edward J Dropcho; Sabine M Wittemer; Johannes Nippgen; Martin Picard; L Burt Nabors
Journal:  J Clin Oncol       Date:  2008-11-03       Impact factor: 44.544

Review 4.  Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.

Authors:  David A Reardon; L Burt Nabors; Roger Stupp; Tom Mikkelsen
Journal:  Expert Opin Investig Drugs       Date:  2008-08       Impact factor: 6.206

5.  Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.

Authors:  Tom Mikkelsen; Chaya Brodie; Susan Finniss; Michael E Berens; Jessica L Rennert; Kevin Nelson; Nancy Lemke; Stephen L Brown; Diane Hahn; Berend Neuteboom; Simon L Goodman
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

6.  The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.

Authors:  Gian Carlo Alghisi; Lionel Ponsonnet; Curzio Rüegg
Journal:  PLoS One       Date:  2009-02-12       Impact factor: 3.240

7.  Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.

Authors:  Andrew R Reynolds; Ian R Hart; Alan R Watson; Jonathan C Welti; Rita G Silva; Stephen D Robinson; Georges Da Violante; Morgane Gourlaouen; Mishal Salih; Matt C Jones; Dylan T Jones; Garry Saunders; Vassiliki Kostourou; Françoise Perron-Sierra; Jim C Norman; Gordon C Tucker; Kairbaan M Hodivala-Dilke
Journal:  Nat Med       Date:  2009-03-22       Impact factor: 53.440
  7 in total
  7 in total

Review 1.  Pathway inhibition: emerging molecular targets for treating glioblastoma.

Authors:  Wolfgang Wick; Michael Weller; Markus Weiler; Tracy Batchelor; Alfred W K Yung; Michael Platten
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

Review 2.  Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.

Authors:  Wolfgang Wick; Antje Wick; Markus Weiler; Michael Weller
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

Review 3.  Targeting integrins in malignant glioma.

Authors:  Ghazaleh Tabatabai; Michael Weller; Burt Nabors; Martin Picard; David Reardon; Tom Mikkelsen; Curzio Ruegg; Roger Stupp
Journal:  Target Oncol       Date:  2010-09-04       Impact factor: 4.493

Review 4.  Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.

Authors:  Carlos Mas-Moruno; Florian Rechenmacher; Horst Kessler
Journal:  Anticancer Agents Med Chem       Date:  2010-12       Impact factor: 2.505

5.  Insulin-like growth factor binding protein-3 inhibits cell adhesion via suppression of integrin β4 expression.

Authors:  Hyo-Jong Lee; Ji-Sun Lee; Su Jung Hwang; Ho-Young Lee
Journal:  Oncotarget       Date:  2015-06-20

6.  Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer.

Authors:  Andrew R Reynolds
Journal:  Dose Response       Date:  2010-04-23       Impact factor: 2.658

7.  RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.

Authors:  Mark Sutherland; Andrew Gordon; Steven D Shnyder; Laurence H Patterson; Helen M Sheldrake
Journal:  Cancers (Basel)       Date:  2012-10-26       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.